Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

Fingers4Cure

Financiado

Zinc finger gene therapy in the brain for treating Huntington s disease

Huntington’s disease (HD) is a lethal inherited neurodegenerative disorder which currently has no cure. Patients develop a devastating loss of muscle control and brain function, with symptoms typically developing at 35 - 45 years... ver más

31/07/2016

IMPERIAL COLLEGE O...

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND ME... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2016-07-31

ERC-PoC-2014: ERC Proof of Concept Grant Scope:Objectives

I+D

Cerrada hace 10 años

0% 100% 100%

2 Participantes

IMPERIAL COLLEGE OF SCIENCE...

150.00K€ | Lider

TALLERES AGA, S.A.

211.55K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

RTC-2015-3731-1 OPTIMIZACIÓN Y DESARROLLO DE UN AGENTE TERAPÉUTICO BASADO EN... 497K€ Cerrado

RTC-2015-3751-1 NUEVAS TECNOLOGÍAS DE FORMULACIÓN PARA LA MEJORA DEL ACCESO... 201K€ Cerrado

TARGETNMDs A novel and empowered TARGETed gene addition approach at a r... 2M€ Cerrado

RTC2019-006995-1 Desarrollo de un fármaco innovador de terapia génica para el... 485K€ Cerrado

SAF2013-42347-R FACTORES NEUROTROFICOS NANOENCAPSULADOS Y TERAPIA GENICA PAR... 242K€ Cerrado

PID2020-116474RB-I00 DESCIFRANDO EL PAPEL DE LA METILACION M6A DEL ARN COMO UN NU... 169K€ Cerrado

Duración del proyecto: 18 meses Fecha Inicio: 2015-01-28
Fecha Fin: 2016-07-31

Líder del proyecto

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND ME... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto Huntington’s disease (HD) is a lethal inherited neurodegenerative disorder which currently has no cure. Patients develop a devastating loss of muscle control and brain function, with symptoms typically developing at 35 - 45 years of age, although they can start much earlier. Suffering is high for both patients and carers, with death generally occurring within 10 - 15 years of diagnosis. We are working on a novel, curative gene therapy approach based on reducing the levels of the HTT disease gene products, while maintaining the levels of the normal protein. It is based on the delivery of proprietary zinc finger proteins (ZFPs) to the brain. Efficient delivery is accomplished through the use of viral vectors that carry the sequences coding for our ZFPs. Such ZFPs are artificially engineered proteins that specifically bind the defective expanded HTT DNA sequences (but not the normal HTT sequences or other, unrelated sequences). Binding represses the synthesis of the toxic gene products. We have published data demonstrating efficient mutant HTT repression in mouse (Garriga-Canut, M., et al. & Isalan M. Synthetic zinc finger repressors reduce mutant Huntingtin expression in the brain of R6/2 mice. Proc Natl Acad Sci USA 109: E3136-E3145, 2012). We now need to improve the viral vectors for the long term expression of our ZFPs in the mouse brain, as the basis for a single-intervention, long-term therapy in humans (technical improvements). In parallel, we need to maintain the patent applications that protect the technology through various national and regional phases, and protect new developments that may arise (intellectual property), while engaging the necessary IPR and market studies/activities that help us find an industry partner that licenses our technology and moves it forward into the clinic (exploitation). This proof of concept grant is critical in all three aspects.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores